FDA grants priority review to VOLGA regimen in bladder cancer
FDA action · Oncodaily · 2026-09-26. Number 3 in the UrologyWatch Top 5 for September 28, 2026.
A company representative noted FDA priority review for a combination regimen (VOLGA) targeting a bladder cancer indication, according to a brief interview item.
Why it matters: Priority review timelines could bring a new perioperative or metastatic urothelial regimen to market sooner.
Source: Oncodaily
Loading today's edition…